Studies addressing rheumatoid arthritis (RA) flares, a potential new drug for psoriatic arthritis, and a novel agent in the treatment of active RA are among the highlights
Search results for: Biologics
The ACR Helps Members Meet Insurance Challenges
The Affiliate Society Council (ASC) and Insurance Subcommittee (ISC) support rheumatologists at a local level, while serving as a national voice for members
ACR/ARHP Annual Meeting 2012: Identify Compliance Risks to Avoid Violating Medicare Rules
Rheumatologists should develop a plan to keep in step with federal regulations
CORRONA Team Provides Data-Based Tool to Address Rheumatology’s Questions
The Consortium of Rheumatology Researchers of North America (CORRONA) patient registry collects a host of treatment and disease indicators for a variety of rheumatic diseases at every physician visit
Rheumatology Drug Updates: Apremilast, Golimumab, and More
Information on new approvals and medication safety rheumatologists need to know
EULAR 2012: Rewards in Risk Factor Research
Investigations of infection and comorbidities offers hints to better understanding of rheumatoid arthritis.
EULAR 2012: Partnership Between Physician and Patient
Patient involvement a valuable tool, especially in less common rheumatic disorders.
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety
EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
Advances in the rheumatology clinic are promising, two experts say.
American College of Rheumatology Leads Charge to Address Excessive Patient Cost Sharing
The ACR Government Affairs Committee has developed legislative language to limit commercial insurance plans’ cost-sharing requirements for medications in a specialty drug tier to the dollar amount applicable to drugs in the nonpreferred-brand drug tier.
- « Previous Page
- 1
- …
- 66
- 67
- 68
- 69
- 70
- …
- 76
- Next Page »